When was Acorda founded?

Acorda was founded in 1995 and raised its 1st funding round 8 years after it was founded.

Where is Acorda located?

Acorda is headquartered in Ardsley, United States.

How many employees does Acorda have?

As of Sep 30, 2026, the latest employee count at Acorda is 166.

Is Acorda a funded company?

Acorda is a funded company, having raised a total of $66.5M across 4 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on May 09, 2003.

How much is Acorda worth?

The last known valuation of Acorda was $***** as of May 15, 2024.

When was the latest funding round of Acorda?

Acorda's latest funding was a $***** Grant (prize money) round on Sep 30, 2011, with participation from 1 investor.

Where does Acorda rank among its competitors?

Acorda ranks 281st amongst 3085 active competitors, of which 1031 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Acorda?

Acorda's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Acorda - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Acorda an acquired company?

Acorda got acquired by Merz on May 15, 2024.

Acorda is an acquired company based in Ardsley (United States), founded in 1995. It operates as a Developer of therapies that restore neurological function. Acorda has raised $66.5M in funding, with last known valuation of $*****. The company has 3085 active competitors, including 1031 funded and 732 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapies that restore neurological function. The company is engaged in the development and commercialization of therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system. The company's product include Ampyra (dalfampridine) Extended Release Tablets (Ampyra), as a treatment to improve walking in patients with MS.

Website: acorda.com/cgi-sys/suspendedpage.cgi
Social

Key Metrics

Founded Year

1995

Location

Ardsley, United States

Stage

Acquired

Total Funding

$66.5M in 4 rounds

Latest Funding Round

Grant (prize money), Sep 30, 2011, $*****

Last Known Valuation

$***** as on May 15, 2024

Investors

Saints Capital & 17 more

Ranked

281^st among 3085 active competitors

Employee Count

166 as on Sep 30, 2026

Investment & Acquisitions

Biotie & 2 more

Similar Companies

Jazz Pharmaceuticals & 929 more

Exit Details

Acquired by Merz (May 15, 2024)

View Acorda's full profile

Acorda is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ACORDA THERAPEUTICS INC CIN: 1008848 , United States, Active	Mar 16, 1995	-	-	-
ACORDA THERAPEUTICS, INC. CIN: 133831168 , United States, Active	Dec 31, 1999	-	103 (As on Dec 31, 2023)	-

Acorda got acquired by Merz on May 15, 2024 at an acquisition amount of $*****.

Click here to take a look at Acorda's acquisition in detail

Acorda has raised a total funding of $66.5M over 4 rounds. Its first funding round was on May 09, 2003. Its latest funding round was a Grant (prize money) round on Sep 30, 2011 for $*****. 1 investor participated in its latest round. Acorda has 18 institutional investors.

Here is the list of recent funding rounds of Acorda:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2011	6238981	Grant (prize money)	4494752	3602896	8037339	3489079
Oct 2006	3190965	Post IPO	9943698	6819396	8291472	9483657
Mar 2004	1311720	Series C	6393032	7173031	8563985	9608776

Access funding benchmarks and valuations. Sign up today!

View details of Acorda's funding rounds and investors

Acorda's employee count trend

Acorda has 166 employees as of Sep 26. Here is Acorda's employee count trend over the years:

Uncover Acorda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acorda include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Acorda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
281st	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	Saints Capital, Abn Amro & 16 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Acorda's competitors? Click here to see the top ones

Acorda has acquired 3 companies including Biotie, Civitas Therapeutics and Neuronex. Acorda has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 19, 2016	Acquisition	Biotie	1998	Turku (Finland)
Sep 24, 2014	Acquisition	Civitas Therapeutics	2009	Chelsea (United States)
Feb 17, 2012	Acquisition	Neuronex	2010	Morrisville (United States)